On June 9, GenScript Biotech fell 5.05% in regular trading, trading at HKD 11.48/share, with trading volume of approximately HKD 99.68 million.

On the news front, the pharmaceutical outsourcing (CXO) sector continued to weaken broadly, with significant sector-wide linkage effects. In the prior trading session, WuXi Biologics fell over 7%, WuXi XDC fell over 6%, and Pharmaron fell over 6%, reflecting collective industry pressure. Concurrently, renewed market concerns over a potential US policy to restrict or even prohibit investment in Chinese novel drug R&D further suppressed risk appetite across the biomedical sector.

Within the Life Sciences Tools & Services sector, stocks declined broadly: WuXi Biologics down 4.41%, WuXi AppTec down 6.84%, XtalPi down 3.38%, WuXi XDC down 4.57%, and Insilico down 3.25%. Although GenScript recently signaled improved profitability and capital return expectations at its annual shareholders meeting, policy uncertainty and systematic sector selling pressure continue to dominate short-term price action.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)